Plecanatide: Phase IIa data

Synergy Pharmaceuticals Inc. (OTCBB:SGYP, New York, N.Y.) reported data from a double-blind, dose-escalation Phase IIa safety trial in 78 patients showing that 0.3, 1, 3 and 9 mg doses of once-daily oral plecanatide for 14 days led to increased frequency of bowel movements and decreased straining and abdominal discomfort vs. placebo. There were no severe adverse events or reports of diarrhea in patients receiving plecanatide, and no systemic absorption of the compound was detected at any dose level. Data were presented at the American College of Gastroenterology meeting in San Antonio. ...